BOARD-ADVISORS-AG
3.11.2021 11:22:10 CET | Business Wire | Press release
LEA Partners GmbH (LEA), a private equity and venture capital investor based in Karlsruhe, Germany, today announced the acquisition of Base-Net Informatik AG (Base-Net), a Swiss software provider leading in the field of credit and mortgage management.
Board Advisors Deutschland AG acted as the exclusive M&A advisor to the shareholders of Base-Net. The team of Christoph Löslein, Urs Niederberger, Felix Brokatzky and Federico Arcelli was able to successfully complete the transaction in less than five months.
"I am extremely pleased that, through the efforts of Board Advisors, we were able to find a new majority shareholder that is equally beneficial to the customers and employees of Base-Net Informatik AG. Despite a complex transaction structure, the advisors of Board Advisors had the mandate under control at all times, were able to successfully complete the project in a record-breaking time and to the full satisfaction of the shareholders."
Stefan Hermann, Founder and Chairman of the Board of Base-Net Informatik AG
Base-Net, headquartered in Sursee in the canton of Lucerne, was founded in 1994. With its WinCredit software it is the leading Swiss software provider in the field of credit and mortgage management. Currently, over 400 banks, insurance companies, pension funds and financial intermediaries use the company's software. In addition, Base-Net develops and operates a state-of-the-art platform for credit and mortgage refinancing.
"The market for credit management software is continuously growing and is highly attractive for us. Therefore, we are very pleased to have gained Base-Net, another leading and long-established company, for us. With this, we are taking another step in building a leading financial services platform in the DACH region."
Philipp Hertel, Partner at LEA
About Base-Net
Base-Net is the leading Swiss software provider in the field of credit and mortgage management. In addition to its loan management software, its solutions for refinancing and exchanges with the Swiss Pfandbriefbank are among the standard solutions in the Swiss financial sector. Founded in 1994 and based in Sursee, the company now serves around 400 banks and insurance companies. For more information, please visit www.basenet.ch .
About LEA Partners
LEA Partners is an entrepreneurial equity partner supporting founders and management teams in different stages of development to grow and achieve a leading market position. Based in Karlsruhe, one of the largest technology clusters in Europe, LEA Partners has managed investments in numerous technology companies since 2002. Following the merger of PROCAD, keytech and ACATEC in May 2021 and that of TAIFUN, M-Soft and PinnCalc in October 2021, the establishment of a buy-and-build platform in the financial services sector, which already includes the b+m Group in addition to Base-Net Informatik AG, represents the next significant transaction for the LEA B2B Tech funds focused on software companies from the DACH region. For more information, please visit www.leapartners.de .
About Board Advisors
Board Advisors is a Management Consulting and M&A advisory firm founded in 2005 by Christoph Löslein and is today headquarted in Freiburg im Breisgau. Board Advisors currently has own operations in Berlin, Zurich, Sursee, Basel, Nice, Munich and Manchester and has a network of international cooperation partners.
Board Advisors has in-depth expertise in the health and technology sectors and has successfully completed numerous business development projects, buy- & sell-side transactions and fundraising mandates in recent years. For further information, please visit www.boardadvisors.de .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005562/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom